ArticleNature biotechnology2008
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Article in Nature biotechnology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 119 citations in OpenAlex.
- Advancing adoptive cellular immunotherapy via Notch-based ex vivo T cell development platforms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.Biomolecules · 2024Review
- Current progress in CAR-based therapy for kidney disease.Frontiers in immunology · 2024Review
- CARs: a new approach for the treatment of autoimmune diseases.Science China. Life sciences · 2023Review
- The potential role of the thymus in immunotherapies for acute myeloid leukemia.Frontiers in immunology · 2023Review
- T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all.Cellular & molecular immunology · 2022Article
- Current Progress of CAR-NK Therapy in Cancer Treatment.Cancers · 2022Review
- Progress on methods of T lymphocyte developmentZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Article
- Thymus Reconstitution in Young and Aged Mice Is Facilitated byFrontiers in immunology · 2022Article
- T-Cell Progenitors As A New Immunotherapy to Bypass Hurdles of Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Review
- Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.Cancer treatment and research · 2022Review
- T cell regeneration after immunological injury.Nature reviews. Immunology · 2021Review
- The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.Seminars in immunopathology · 2021Review
- CAR T cells in solid tumors: challenges and opportunities.Stem cell research & therapy · 2021Review
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nature reviews. Clinical oncology · 2020Review
- Thymic Engraftment byFrontiers in immunology · 2020Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
Abstract
We present a strategy for adoptive immunotherapy using T-lineage committed lymphoid precursor cells generated by Notch1-based culture. We found that allogeneic T-cell precursors can be transferred to irradiated individuals irrespective of major histocompatibility complex (MHC) disparities and give rise to host-MHC restricted and host-tolerant functional allogeneic T cells, improving survival in irradiated recipients as well as enhancing anti-tumor responses. T-cell precursors transduced to express a chimeric receptor targeting hCD19 resulted in significant additional anti-tumor activity, demonstrating the feasibility of genetic engineering of these cells. We conclude that ex vivo generated MHC-disparate T-cell precursors from any donor can be used universally for 'off-the-shelf' immunotherapy, and can be further enhanced by genetic engineering for targeted immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.